MoonLake Immunotherapeutics MLTX Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on trailing twelve months.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's return on invested capital?
- MoonLake Immunotherapeutics (MLTX) reported return on invested capital of -199.6% in Q1 2026.
- How has MoonLake Immunotherapeutics's return on invested capital changed year-over-year?
- MoonLake Immunotherapeutics's return on invested capital decreased by 75.0% year-over-year, from -114.1% to -199.6%.
- What is the long-term trend for MoonLake Immunotherapeutics's return on invested capital?
- Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's return on invested capital has grown at a -8.8% compound annual growth rate (CAGR), from -187% to -155.5%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.